Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Veena Hoffman"'
Autor:
Thomas Keens, Veena Hoffman, Ia Topuria, Ken Elder, Shannon Cerf, Kyra Mulder, Jon Roberts, Jerimiah Lysinger, Maria Del Carmen Reyes, Maria Berdella, Anne Marie Cairns, Manu Jain, Vaidyanathan Ganapathy, Yiyue Lou, Bassem Morcos, Chuntao Wu, Laura Sass
Publikováno v:
Heliyon, Vol 10, Iss 7, Pp e28508- (2024)
Background: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (CF) aged ≥2 years. Here, we describe results from an observational study assessing change in burden of illness foll
Externí odkaz:
https://doaj.org/article/9304463ac983441caa1631b1fb16f40b
Autor:
Veena Hoffman, Remon Abu-Elyazeed, Cheryl Enger, Daina B. Esposito, Michael C. Doherty, Scott C. Quinlan, Kathleen Skerry, Crystal N. Holick, Peter Basile, Leonard R. Friedland, Nicolas Praet, Stéphanie Wéry, Corinne Willame, David D. Dore, Dominique Rosillon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 7, Pp 1782-1790 (2018)
As part of a regulatory commitment for post-licensure safety monitoring of live, oral human rotavirus vaccine (RV1), this study compared the incidence rates (IR) of intussusception, acute lower respiratory tract infection (LRTI) hospitalization, Kawa
Externí odkaz:
https://doaj.org/article/fd62db0cd2c14cfb95d4cddea76b6f3e
Publikováno v:
Current Medical Research and Opinion. :1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9501d84299a821d4004b75e15649e972
https://doi.org/10.1080/03007995.2023.2194776
https://doi.org/10.1080/03007995.2023.2194776
Autor:
Andrea K. Chomistek, Veena Hoffman, Robert Urman, Karminder S. Gill, Stephen M. Ezzy, Li Zhou, Andrew S. Park, Brett Loop, Sandra Lopez-Leon, Peter McAllister, Florence T. Wang
Publikováno v:
Pain and Therapy. 11:1415-1437
Erenumab, an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody (mAb), was approved by the US Food and Drug Administration in May 2018. Constipation with serious complications was added to the Warning and Precautions section in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9ca19f552e28f0df44eaa935b0b61e2
https://doi.org/10.1007/s40122-022-00440-7
https://doi.org/10.1007/s40122-022-00440-7
Autor:
Veena, Hoffman, Kathleen M, Mortimer, Kyra, Mulder, Ia, Topuria, Richard, Gliklich, James E, Kallman
Publikováno v:
Current Medical Research and Opinion. 38:375-381
To compare healthcare resource use (HCRU) in patients undergoing sinus surgery with or without steroid-eluting sinus implants.A retrospective, observational cohort study using real-world evidence data (OM1, Inc, Boston, MA, USA) was conducted on adul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::187edcde9a7699b527cf7f234acc1638
https://doi.org/10.1080/03007995.2021.2022874
https://doi.org/10.1080/03007995.2021.2022874
Autor:
Kathryn Starzyk, Veena Hoffman, Zhaohui Su, Roger Meng, Mudit Bhartia, Gary Curhan, Kazuki Yoshida, Jessica K. Paulus
Publikováno v:
Arthritis & Rheumatology. 75:328-329
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5e6546c24c4b096a4c79e7102be730e
https://doi.org/10.1002/art.42398
https://doi.org/10.1002/art.42398
Autor:
Cheryl Enger, Libby Horter, Nina Sahlertz Kristiansen, Stefan de Vogel, Kelesitse Phiri, Brandon T. Suehs, Jesper Hallas, Alejandro Arana, Marie Linder, Ingvild Odsbu, Yihua Xu, Andrea V. Margulis, Kwame Appenteng, John D. Seeger, Morten Olesen, Veena Hoffman, Susana Perez-Gutthann
Publikováno v:
Hoffman, V, Hallas, J, Linder, M, Margulis, A, Suehs, B T, Arana, A, Phiri, K, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Xu, Y, Kristiansen, N S, Appenteng, K, de Vogel, S, Seeger, J D & the mirabegron PMR-PASS study group 2021, ' Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder : Findings from a Non-Interventional, Multinational, Cohort Study ', Drug Safety, vol. 44, no. 8, pp. 899-915 . https://doi.org/10.1007/s40264-021-01095-7
Drug Safety
Drug Safety
Introduction During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients with overactive bladder. Objective The purpose of this study was to compare incidence rates of adverse car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606ed98949016a3becf28423411ba054
https://findresearcher.sdu.dk:8443/ws/files/191412893/Hoffman2021_Article_CardiovascularRiskInUsersOfMir.pdf
https://findresearcher.sdu.dk:8443/ws/files/191412893/Hoffman2021_Article_CardiovascularRiskInUsersOfMir.pdf
Autor:
John D. Seeger, Marie Linder, Veena Hoffman, Alejandro Arana, Shahram Bahmanyar, Susana Perez-Gutthann, Jesper Hallas, Libby Horter, Brandon T. Suehs, Stefan de Vogel, Kelesitse Phiri, Nina Sahlertz Kristiansen, Andrea V. Margulis, Ingvild Odsbu, Kwame Appenteng, Cheryl Enger, Morten Olesen
Publikováno v:
Phiri, K, Hallas, J, Linder, M, Margulis, A, Suehs, B, Arana, A, Bahmanyar, S, Hoffman, V, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Kristiansen, N S, Appenteng, K, de Vogel, S & Seeger, J 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion, vol. 37, no. 5, pp. 867-877 . https://doi.org/10.1080/03007995.2021.1891035
the Mirabegron PMR-PASS study group 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion . https://doi.org/10.1080/03007995.2021.1891035
the Mirabegron PMR-PASS study group 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion . https://doi.org/10.1080/03007995.2021.1891035
Objective: This post-authorization safety study (EU PAS Register Number: EUPAS16088) was designedto compare the incidence of cancer outcomes in patients treated with mirabegron versus antimuscarinicmedications.Methods: Cohorts of mirabegron initiator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e16fdb16219dfcf888757ab899a0540
https://pubmed.ncbi.nlm.nih.gov/33591859
https://pubmed.ncbi.nlm.nih.gov/33591859
Autor:
John D. Seeger, Stefan de Vogel, Andrea V. Margulis, Susana Perez Gutthann, Jesper Hallas, Kwame Appenteng, Brandon T. Suehs, Alejandro Arana, Morten S. Olesen, Nina Sahlertz Kristiansen, Cheryl Enger, Libby Horter, Veena Hoffman, Yihua Xu, Ingvild Odsbu, Marie Linder
Publikováno v:
Circulation. 142
Introduction: During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased heart rate and systolic/diastolic blood pressure vs placebo in patients with overactive bladder (OAB). We studied the association between mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1db0f2fc25a27e7aa2733f01192df96a
https://doi.org/10.1161/circ.142.suppl_3.13154
https://doi.org/10.1161/circ.142.suppl_3.13154
Autor:
Peter Basile, Cheryl Enger, Leonard R. Friedland, Corinne Willame, Kathleen Skerry, David D. Dore, Remon Abu-Elyazeed, Stéphanie Wéry, Dominique Rosillon, M. C. Doherty, Daina B. Esposito, Nicolas Praet, Crystal N. Holick, Scott C. Quinlan, Veena Hoffman
Publikováno v:
Human Vaccines & Immunotherapeutics
As part of a regulatory commitment for post-licensure safety monitoring of live, oral human rotavirus vaccine (RV1), this study compared the incidence rates (IR) of intussusception, acute lower respiratory tract infection (LRTI) hospitalization, Kawa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b3dbddaac98ae310408bad6aec72a4
https://doi.org/10.1080/21645515.2018.1450123
https://doi.org/10.1080/21645515.2018.1450123